Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells

HSP90 inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) which is currently in phase II/III clinical trials, are promising new anticancer agents. Here, we explored acquired resistance to HSP90 inhibitors in glioblastoma, a primary brain tumor with poor prognosis. Gliob...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gaspar, Nathalie, Sharp, Swee Y, Pacey, Simon, Jones, Chris, Walton, Michael, Vassal, Gilles, Eccles, Suzanne, Pearson, Andrew, Workman, Paul
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2652695/
https://ncbi.nlm.nih.gov/pubmed/19244114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-3131
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars